Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOOTPATH: Optimal first-line chemotherapy for metastatic pancreatic cancer
2017-003496-54Phase 2Completed
- Sponsor
- LMU Klinikum
- Start
- Aug 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine, paclitaxel, irinotecan liposome, fluorouracil, folinic acid and 1 more in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by LMU Klinikum. Primary endpoint: Progression-free survival. Started Aug 2018; status: completed.
02
Drugs
gemcitabinepaclitaxelirinotecan liposomefluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2017-003496-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003496-54.